Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.

ClinicalTrials.gov ID: NCT00380939

Public ClinicalTrials.gov record NCT00380939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy. A substudy will examine the effect of these treatments on brachial artery vasoactivity.

Study identification

NCT ID
NCT00380939
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
30 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 1999
Primary completion
Not listed
Completion
Nov 30, 2000
Last update posted
Dec 3, 2006

1999 – 2000

United States locations

U.S. sites
36
U.S. states
20
U.S. cities
33
Facility City State ZIP Site status
Pfizer Investigational Site Little Rock Arkansas 72205
Pfizer Investigational Site Los Angeles California 90048
Pfizer Investigational Site Los Angeles California 90095
Pfizer Investigational Site San Diego California 92103-8411
Pfizer Investigational Site Denver Colorado 80262
Pfizer Investigational Site BLUE Island Florida 60406
Pfizer Investigational Site Gainesville Florida 32610
Pfizer Investigational Site Atlanta Georgia 30309
Pfizer Investigational Site Chicago Illinois 60637
Pfizer Investigational Site Shawnee Mission Kansas 66204
Pfizer Investigational Site Louisville Kentucky 40202
Pfizer Investigational Site Auburn Maine 04210
Pfizer Investigational Site Boston Massachusetts 02111
Pfizer Investigational Site Kalamazoo Michigan 49001
Pfizer Investigational Site Royal Oak Michigan 48073
Pfizer Investigational Site Saint Clair Michigan 48080
Pfizer Investigational Site Rochester Minnesota 55905
Pfizer Investigational Site Albany New York 12208
Pfizer Investigational Site New York New York 10029
Pfizer Investigational Site Williamsville New York 14221
Pfizer Investigational Site Chapel Hill North Carolina 27599-7594
Pfizer Investigational Site Greensboro North Carolina 27403
Pfizer Investigational Site Greenville North Carolina 27858-4354
Pfizer Investigational Site Winston-Salem North Carolina 27157
Pfizer Investigational Site Cleveland Ohio 44106
Pfizer Investigational Site Cleveland Ohio 44195-5066
Pfizer Investigational Site Columbus Ohio 43210
Pfizer Investigational Site Elryia Ohio 44035
Pfizer Investigational Site Toledo Ohio 43614
Pfizer Investigational Site Tulsa Oklahoma
Pfizer Investigational Site Allentown Pennsylvania 18106
Pfizer Investigational Site Philadelphia Pennsylvania 19107
Pfizer Investigational Site Providence Rhode Island 02903
Pfizer Investigational Site Providence Rhode Island 02906
Pfizer Investigational Site San Antonio Texas 78284-6205
Pfizer Investigational Site Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00380939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 3, 2006 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00380939 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →